FIELD: biotechnology.
SUBSTANCE: group of inventions relates to biotechnology, immunology and virology. Humanized monoclonal antibody is created, that specifically binds to RBD S of the protein of the SARS-CoV-2 virus and has virus-neutralizing activity, as well as an agent and a method for therapy and emergency prevention of diseases caused by SARS-CoV-2 virus. Humanized monoclonal antibody has the heavy chain amino acid sequence SEQ ID NO: 1 and the light chain amino acid sequence SEQ ID NO: 2. Also disclosed is a method for therapy and emergency prevention of viral infection SARS-CoV-2.
EFFECT: group of inventions extends the range of agents having virus-neutralizing activity and protective activity against various strains of the SARS-CoV-2 virus.
3 cl, 7 dwg, 7 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MEANS AND METHOD FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY THE SARS-COV-2 VIRUS BASED ON A RECOMBINANT ANTIBODY AND A HUMANIZED MONOCLONAL ANTIBODY | 2021 |
|
RU2769223C1 |
| SINGLE-DOMAIN ANTIBODY AND ITS MODIFICATIONS THAT SPECIFICALLY BIND TO RBDS PROTEIN OF SARS-COV-2 VIRUS, AND METHOD FOR THEIR USE FOR THERAPY AND EMERGENCY PREVENTION OF DISEASES CAUSED BY SARS- COV-2 VIRUS | 2021 |
|
RU2763001C1 |
| AAV5-BASED VACCINE FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-COV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-COV-2 | 2020 |
|
RU2760301C1 |
| VACCINE BASED ON AAV5 FOR INDUCTION OF SPECIFIC IMMUNITY TO SARS-CoV-2 VIRUS AND/OR PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2020 |
|
RU2783313C1 |
| VACCINE BASED ON AAV5 FOR THE INDUCTION OF SPECIFIC IMMUNITY TO THE SARS-CoV-2 VIRUS AND/OR THE PREVENTION OF CORONAVIRUS INFECTION CAUSED BY SARS-CoV-2 | 2021 |
|
RU2761879C1 |
| PROTEIN AND VACCINE AGAINST SARS-CoV-2 INFECTION | 2020 |
|
RU2815060C1 |
| ISOLATED RECOMBINANT VIRUS BASED ON INFLUENZA VIRUS FOR INDUCING SPECIFIC IMMUNITY TO INFLUENZA VIRUS AND/OR PREVENTING DISEASES CAUSED BY INFLUENZA VIRUS | 2021 |
|
RU2813150C2 |
| GENE CONSTRUCT FOR THE EXPRESSION OF RECOMBINANT PROTEINS BASED ON THE SEGMENT OF THE SARS-COV-2 S-PROTEIN, INCLUDING RBD AND SD1, FUSED WITH THE FC FRAGMENT OF IGG, A METHOD OF OBTAINING RECOMBINANT PROTEINS, ANTIGENS AND ANTIGENIC COMPOSITIONS FOR THE INDUCTION OF LONG-TERM ANTIBODY AND CELLULAR IMMUNITY AGAINST SARS-CO-2 | 2021 |
|
RU2802825C2 |
| METHOD FOR DETECTING SARS-COV-2 VIRUS BY MASS SPECTROMETRY | 2021 |
|
RU2748540C1 |
| RECOMBINANT DNA ENSURING PRODUCTION OF THE RECOMBINANT PROTEIN COV1 EXHIBITING IMMUNOGENIC PROPERTIES AGAINST SARS-COV-2 VIRUS | 2021 |
|
RU2776484C1 |
